Azienda Socio Sanitaria Locale N 2 Della Gallura
- Address
- lock Available on a paid plan
Cardiovascular and Kidney Research
At Azienda Socio Sanitaria Locale N 2 Della Gallura in Olbia, clinical research in cardiovascular diseases and nutritional and metabolic diseases is focused on people living with type 2 diabetes mellitus and chronic kidney disease. The studies are designed to better understand whether new treatment combinations can improve kidney and heart outcomes while supporting standard care.
- Evaluating whether combined therapy can reduce kidney damage markers more effectively than single treatments
- Assessing treatments aimed at lowering major cardiovascular event risk in patients with diabetes
- Studying therapies that may improve both metabolic control and long-term organ protection
These trials reflect a strong interest in improving treatment effectiveness for patients with overlapping heart, kidney, and diabetes-related conditions.
Inflammatory and Immune System Research
The site also contributes to immune system disease research through studies in rare inflammatory conditions such as PAPA syndrome. This work explores whether targeted anti-inflammatory treatment can provide meaningful benefit for patients with difficult-to-manage disease.
- Testing a targeted therapy for a rare autoinflammatory syndrome
- Examining symptom control and disease activity in a complex immune-mediated disorder
- Generating evidence to support better treatment choices in rare inflammatory disease
Research in this area helps advance care for uncommon conditions where treatment options remain limited and clinical evidence is still developing.
Metabolic Disease and Cardiometabolic Outcomes
Another important theme at this hospital/clinic is the study of therapies for type 2 diabetes mellitus with a focus on broader cardiometabolic outcomes. The research is aimed at understanding whether newer treatments can improve cardiovascular protection alongside glucose management.
- Comparing diabetes treatments for their effect on major heart and stroke outcomes
- Exploring whether newer metabolic therapies offer added benefit beyond standard treatment
- Supporting better long-term care for patients at high cardiovascular risk
This line of research brings together cardiovascular and metabolic care, with the goal of improving both disease control and patient outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Nuvation Bio Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Socio Sanitaria Locale N 2 Della Gallura
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Assessment of Finerenone and Empagliflozin Combination Versus Monotherapy in Chronic Kidney Disease with Type 2 Diabetes | Bayer AG | Phase II | Not Recruiting | May 2022 | Feb 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Canakinumab | 1 | Unknown | 2024-02-02 | 2024-02-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.